My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 723 / DOI: 10.3332/ecancer.2017.723

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Keywords: ovarian cancer, metronomic chemotherapy, cyclophosphamide

Loading Article Metrics ... Please wait

Related articles

Conference Report: Conference report on the Indo Global Summit on Head and Neck Oncology (IGSHNO 2017-BMCON-IV), 24–26 February 2017, Jaipur, India

Abstract | Full Article | PDF Published: 31 May 2017 / DOI: 10.3332/ecancer.2017.739

Clinical Study: Perceived utility of an integrated psychological intervention for gynaecological cancer patients admitted for surgery: preliminary data

Abstract | Full Article | PDF Published: 23 Feb 2017 / DOI: 10.3332/ecancer.2017.722

Conference Report: Balancing health care needs in a changing context: nursing highlights from the 2016 European Oncology Nursing Society Congress (EONS10), 17–18 October 2016, Dublin, Ireland

Abstract | Full Article | PDF Published: 05 Jan 2017 / DOI: 10.3332/ecancer.2017.710

Conference Report: Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7–10 October 2016

Abstract | Full Article | PDF Published: 16 Dec 2016 / DOI: 10.3332/ecancer.2016.703

Review: An Australasian perspective on the curative treatment of patients with pancreatic cancer, supportive care, and future directions for management

Abstract | Full Article | PDF Published: 07 Dec 2016 / DOI: 10.3332/ecancer.2016.700



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence